{'fraction_non_alphanumeric': 0.03295750216825672, 'fraction_numerical': 0.030355594102341718, 'mean_word_length': 5.041884816753926, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
145 Nadunolimab inhibits IL-1α/β-induced CXCR1/2 ligand expression and reduces serum levels of CXCL1 and CXCL5 in NSCLC and PDAC patients

Background Interleukin-1 receptor accessory protein (IL1RAP) is expressed on tumor cells and stromal cells in most solid tumors, including PDAC and NSCLC. IL1RAP is a co-receptor of the IL-1 receptor (IL1R1), and its dimerization with IL1R1 is required for IL-1 signaling. IL-1 is expressed in the tumor microenvironment and contribute to chemoresistance and an immune-suppressive tumor microenvironment. The chemokine receptors CXCR1 and CXCR2 and their ligands are crucial for the migration of immune-suppressive cells into the tumor and thereby influences tumor progression and metastasis. CXCR1/2 ligands can be expressed by cells in the tumor microenvironment and are downstream of IL-1 signaling. Nadunolimab is a fully humanized ADCC-enhanced monoclo-nal IgG1 antibody targeting IL1RAP and disrupting both IL-1 a and IL-1 b signaling. Currently, nadunolimab is evaluated in phase II for PDAC and NSCLC (NCT03267316) in combination with gemcitabine + Nab-paclitaxel or gemcitabine + cis-platin, respectively.